z-logo
open-access-imgOpen Access
Cell Polarity, Epithelial-Mesenchymal Transition, and Cell-Fate Decision Gene Expression in Ductal Carcinoma In Situ
Author(s) -
Danila Coradini,
Patrizia Boracchi,
Federico Ambrogi,
Elia Biganzoli,
Saro Oriana
Publication year - 2012
Publication title -
international journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 22
eISSN - 2090-1410
pISSN - 2090-1402
DOI - 10.1155/2012/984346
Subject(s) - epithelial–mesenchymal transition , polarity (international relations) , cancer research , mesenchymal stem cell , cell polarity , cell , cell fate determination , ductal carcinoma , microbiology and biotechnology , computational biology , in situ , gene expression , biology , gene , medicine , transition (genetics) , bioinformatics , chemistry , genetics , cancer , transcription factor , breast cancer , organic chemistry
Loss of epithelial cell identity and acquisition of mesenchymal features are early events in the neoplastic transformation of mammary cells. We investigated the pattern of expression of a selected panel of genes associated with cell polarity and apical junction complex or involved in TGF- β -mediated epithelial-mesenchymal transition and cell-fate decision in a series of DCIS and corresponding patient-matched normal tissue. Additionally, we compared DCIS gene profile with that of atypical ductal hyperplasia (ADH) from the same patient. Statistical analysis identified a “core” of genes differentially expressed in both precursors with respect to the corresponding normal tissue mainly associated with a terminally differentiated luminal estrogen-dependent phenotype, in agreement with the model according to which ER-positive invasive breast cancer derives from ER-positive progenitor cells, and with an autocrine production of estrogens through androgens conversion. Although preliminary, present findings provide transcriptomic confirmation that, at least for the panel of genes considered in present study, ADH and DCIS are part of a tumorigenic multistep process and strongly arise the necessity for the regulation, maybe using aromatase inhibitors, of the intratumoral and/or circulating concentration of biologically active androgens in DCIS patients to timely hamper abnormal estrogens production and block estrogen-induced cell proliferation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom